From research to the real world: Buprenorphine in the decade of the Clinical Trials Network

Journal of Substance Abuse Treatment

Volumn 38, Issue SUPPL. 1, 2010, Pages

  Ling, Walter ^a   Jacobs, Petra ^b   Hillhouse, Maureen ^a   Hasson, Albert ^a   Thomas, Christie ^a   Freese, Thomas ^a   Sparenborg, Steven ^b   McCarty, Dennis ^c   Weiss, Roger ^d   Saxon, Andrew ^e   Cohen, Allan ^f   Straus, Michele ^b   Brigham, Gregory ^g   Liu, David ^b   McLaughlin, Paul ^h   Tai, Betty ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Puget Sound Health Care System   (United States)

^f Bay Area Addiction Research and Treatment   (United States)

^g Maryhaven   (United States)

^h Hartford Dispensary ^*  (United States)

Author keywords

Buprenorphine; Clinical Trials Network; CTN; Opiate dependence; Opioids; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; NALTREXONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG COST; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HUMAN; OPIATE ADDICTION; PATIENT ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHOSOCIAL CARE;

ADMINISTRATION, SUBLINGUAL; BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; COMMUNITY HEALTH SERVICES; DRUG COMBINATIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID, MU; UNITED STATES;

EID: 77950271251     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2010.01.009     Document Type: Article

References (30)

1. Amass L., Bickel W.K., Higgins S.T., Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases 1994, 13:33-45.
2. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment programs: The NIDA Clinical Trial Network field experience. The American Journal on Addictions 2004, 13:S42-S66.
3. Brigham G.S., Amass L., Winhusen T., Harrer J.M., Pelt A. Using buprenorphine short-term taper to facilitate early treatment engagement. Journal of Substance Abuse Treatment 2007, 32:349-356.
4. CSAT Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 07-3939 2004, Substance Abuse and Mental Health Services Administration, Rockville, MD.
5. Cohen A.J. 2006, (Document No: 117).
6. Collins E.D., Horton T., Reinke K., Amass L., Nunes E.V. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation. Journal of Substance Abuse Treatment 2007, 32:167-175.
7. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., Mattick R.P. Serious adverse events in the Australian National Evaluation of Pahrmacotherapies for Opioid Dependence (NEPOD). Addiction 2004, 99:450-460. and the NEPOD Research Group.
8. Ducharme L., Roman P. Opioid Treatment Programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment 2009, 37:90-94.
9. Ducharme L.J., Knudsen H.K., Roman P.M., Johnson J.A. Innovation adoption in substance abuse treatment: Exposure, trialability and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32:321-329.
10. Fitzgerald J., McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: A multilevel approach. Psychological Services 2009, 6:74-84.
11. Fussell H.E., Kunkel L.E., Lewy C.S., McFarland B.H., McCarty D. Using a standardized patient walk-through to improve implementation of clinical trials. Journal of Substance Abuse Treatment 2008, 35:470-475.
12. Gerra G., Fantoma A., Zalmovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of Psychopharmacology 2006, 20:806-814.
13. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry 1978, 35:501-516.
14. Knudsen H., Abraham A., Johnson J., Roman P. Buprenorphine Adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2009, 37:307-312.
15. Knudsen H.K., Abraham A.J., Roman P.M. Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine 2010, (in press).
16. Knudsen H.K., Ducharme L.J., Roman P.M. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 2006, 30:363-373.
17. Knudsen H.K., Ducharme L.J., Roman P.M. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 2007, 87:164-174.
18. Kovas A.E., McFarland B.F., Boverman J., McCarty D., Thayer J.A. Buprenorphine for acute heroin detoxification: Diffusion of research into practice. Journal of Substance Abuse Treatment 2007, 32:199-206.
19. Ling W., Amass L., Shoptow M., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse's Clinical Trial Network. Addiction 2005, 100:1090-1100.
20. Ling W., Compton P. Recent advances in the treatment of opiate addiction. Clinical Neurosciences Research 2005, 5:161-167.
21. Ling W., Cunningham-Rathner J., Rawson R. Diffusion of substance abuse treatment: Will buprenorphine be a success?. Journal of Psychoactive Drugs 2004, (SARC Supplement 2, May).
22. Ling W., Hillhouse M., Domier C., Doraimani G., Hunter J., Thomas C., et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009, 104:256-265.
23. McCance-Katz E.F. Office-based buprenorphine treatment for opioid-dependent patients. Harvard Review of Psychiatry 2004, 12:321-338.
24. McCarty D., Fuller B.E., Arfken C., Miller M., Nunes E.V., Edmundson E., et al. Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, opinions, and beliefs. Psychiatric Services 2007, 58:181-190.
25. Pirnay S., Borron S.W., Giudicelli C.P., Tourneau J., Baud F.J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: Analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004, 99:978-988.
26. Rogers E.M. Diffusion of Innovations 2003, Free Press, New York. 5th ed.
27. Strain E.C., Walsh S.L., Preston K.L., Liebson I.A., Bigelow G.E. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 1997, 129:329-338.
28. Torrington M.A., Domier C.P., Hillhouse M., Ling W. Buprenorphine 101: Treating opioid dependence with buprenorphine in an office-based setting. Journal of Addictive Diseases 2007, 26:93-99.
29. Weiss R.D., Potter J.S., Copersino M.L., Prather K., Jacobs P., Provost S., et al. Conducting clinical research with prescription opioid dependence: Defining the population. American Journal on Addictions 2010, (in press).
30. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., et al. Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. JAMA 2008, 300:2003-2011.